Viral hepatitis B and C infections in adolescents born pre- and post-hepatitis B vaccine introduction in Calabar, Nigeria
Accepted: 29 June 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Hepatitis B and C Virus (HBV, HCV) infections are major contributors to the burden of chronic liver diseases globally. In a bid to curb the HBV infection, the Nigerian Government introduced the HBV vaccine into the National Program on Immunization (NPI) in 2004.This study aimed to determine the prevalence and associated factors of HBV and HCV infections among adolescents in secondary schools in Calabar, Cross River State, South-South Nigeria, in the pre- and post-vaccination era. This was a school-based, cross-sectional study. Six hundred and sixty secondary school adolescents, aged 10-20 years, were recruited using multi-staged sampling technique. Hepatitis B Surface Antigen (HBsAg) and HCV antibody screening were done respectively on the study participants using rapid chromatographic immunoassay method. The relationship between sociodemographic variables and Hepatitis B infection were described. A p-value of less than 0.05 was considered significant. The mean age of the participants was 14.85±2.11 years. Six participants were positive for HBsAg, giving an overall prevalence of 0.9%. The positive adolescents were from public schools, and the age group mostly positive was 16 years and above (2.1%). None of the screened adolescents was positive for HCV antibody. Though the prevalence of HBV infection was low, most of those positive were delivered before the introduction of the HBV vaccine into the NPI schedule. Modalities to vaccinate young people delivered before the introduction of Hepatitis B vaccine into the NPI schedule should be developed.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.